Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 12/20 | 0.68 |
| ▸ | FNTB | P49356 | 12/20 | 0.68 |
| ▸ | PGGT1B | P53609 | 7/20 | 0.68 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7455926 | 0.99 | FNTA (0.67) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL7559208 | 0.84 | FNTA (0.53) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL12519094 | 0.81 | FNTA (1.00) | FNTAFNTBPGGT1B | |
| SCHEMBL5935187 | 0.81 | FNTA (0.82) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL7259778 | 0.81 | FNTA (0.59) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL6985868 | 0.77 | CYP11B1 (0.61) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL7259741 | 0.77 | FNTA (0.61) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL7255008 | 0.76 | FNTA (0.61) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL6708602 | 0.76 | CYP11B1 (0.52) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL9092712 | 0.75 | CYP11B1 (0.57) | FNTAFNTBPGGT1BCYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1019529-A4 | A METHOD OF TREATING CANCER | MERCK & CO INC (US) | 2002-09-11 | — | — | EP | claimed |
| JP-2001518281-A | — | — | 2001-10-16 | — | — | JP | claimed |
| EP-1019530-A1 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 2000-07-19 | — | — | EP | claimed |
| EP-1019529-A1 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 2000-07-19 | — | — | EP | claimed |
| EP-1009854-A1 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 2000-06-21 | — | — | EP | claimed |
| WO-1999010525-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1999-03-04 | — | — | WO | claimed |
| WO-1999010524-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1999-03-04 | — | — | WO | claimed |
| WO-1999010523-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1999-03-04 | — | — | WO | claimed |
| WO-1999010329-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1999-03-04 | — | — | WO | claimed |
| US-6103487-A | DETECTING MODULATORS THAT SUPPRESS THE ACTIVITY OF A TRANSFERASES; ANTICARCINOGENIC AGENTS | MERCK & CO., INC. (US) | 2000-08-15 | — | — | US | disclosed |
| EP-1019530-A1 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 2000-07-19 | — | — | EP | disclosed |
| EP-1009854-A1 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 2000-06-21 | — | — | EP | disclosed |
| WO-2000016626-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 2000-03-30 | — | — | WO | disclosed |
| WO-1999010524-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1999-03-04 | — | — | WO | disclosed |
| WO-1999010523-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1999-03-04 | — | — | WO | disclosed |
| WO-1999010329-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1999-03-04 | — | — | WO | disclosed |